Previous 10 | Next 10 |
“Medical treatment has made astonishing advances over the years. But the packaging and delivery of that treatment are often inefficient, ineffective, and consumer unfriendly.” That’s what Harvard researchers stated in Why Innovation in Health Care Is So Hard ...
M atthew Owen s appointed General Counsel and Chief Legal Officer ; Lars Wilde, Chief Business Officer and Co-founder, to move into senior advis ory role London, UK – 16 December 2021 COMPASS Pathways plc (Na...
Palm Beach, FL –December 14, 2021 – FinancialNewsMedia.com News Commentary – The prevalence of mental health disorders has risen exponentially, and the development of novel medications has not kept pace, precipitating a crisis in psychiatric medicine. A nove...
Recently, Compass Pathways (NASDAQ: CMPS) released new data on its COMP360 psilocybin therapy , which highlights that there’s no evidence suggesting that psilocybin gives rise to serious adverse events. The data also shows that the treatment could provide benefits beyond decreasi...
COMPASS Pathways plc (Nasdaq: CMPS) announced positive results from its exploratory study of COMP360 psilocybin therapy in conjunction with SSRI use. The study wanted to test whether patients with treatment-resistant depression could tolerate and do well with psilocybin treatm...
Patients taking COMP360 psilocybin with concomitant SSRIs showed comparable treatment outcomes to patients withdrawn from their SSRI therapy in COMPASS’s phase IIb trial All patients tolerated COMP360 psilocybin therapy well London, UK – 13 December...
Atai Life Sciences (NASDAQ: ATAI) , a clinical-stage biopharmaceutical company whose objective is to transform how mental health conditions are treated, has increased its stake in Compass Pathways. Compass Pathways (NASDAQ: CMPS) is a mental health care company that is focused on improvin...
COMPASS Pathways (NASDAQ:CMPS) has appointed Michael Falvey as Chief Financial Officer, suceeding Piers Morgan, effective 1 January 2022. Michael Falvey, most recently served at Karyopharm Therapeutics (NASDAQ:KPTI), where he led the financial strategy and prepared the financial inf...
London, UK - 3 December 2021 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced that it has appointed Michael Falvey as Chief Financial Officer, rep...
COMPASS Pathways plc (Nasdaq: CMPS) announced further results from its groundbreaking phase IIb clinical trial of COMP360 psilocybin therapy for treatment-resistant depression (TRD). Compass said that additional analyses of primary and secondary endpoints validated topli...
News, Short Squeeze, Breakout and More Instantly...
2024-08-01 23:30:19 ET Image source: The Motley Fool. Compass Pathways Plc (NASDAQ: CMPS) Q2 2024 Earnings Call Aug 01, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Compass Pathways Plc (CMPS) Q2 2024 Earnings Call Tr...
Top-line COMP005 data for COMP360 phase 3 pivotal program in treatment-resistant depression expected in fourth quarter 2024 Gino Santini to join Board of Directors as Chairman Lori Englebert named new Chief Commercial Officer Cash position of $228.6 million ...
LONDON, July 24, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the second quarter 2024 ending June 30, 2024, a...